Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability

Clinical Therapeutics
Anthony DeLeonM Lynn Crismon

Abstract

Recently approved for the treatment of schizophrenia, aripiprazole represents the sixth second-generation antipsychotic (SGA) introduced to the US market. Aripiprazole is considered a partial dopaminergic agonist, acting on both postsynaptic dopamine(2) receptors and presynaptic autoreceptors, in addition to displaying partial agonism at serotonin(1A) receptors and antagonism at serotonin(2A) receptors. The aim of this study was to comprehensively review all available literature regarding the mechanism of action, pharmacokinetics, clinical efficacy, and adverse effects of aripiprazole. Relevant data were collected using MEDLINE and International Pharmaceutical Abstracts searches with the terms aripiprazole and OPC-14597 and with no limitations on year. Abstracts and posters presented at national and international scientific meetings were also reviewed. Aripiprazole exhibits linear pharmacokinetics and is administered once daily. In multiple clinical trials, aripiprazole was effective in significantly reducing symptomatology associated with schizophrenia-related disorders compared with placebo (P < 0.05). Dosages > or =15 mg/d more consistently produced significant reductions from baseline of Positive and Negative Syndrome Scale...Continue Reading

References

Jan 16, 1998·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·J Arnt, T Skarsfeldt

❮ Previous
Next ❯

Citations

May 16, 2008·Psychopharmacology·Gunnar SørensenDavid P D Woldbye
Sep 26, 2009·Psychopharmacology·Matthew W FeltensteinRonald E See
Mar 21, 2013·Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences·Daxesh P PatelPranav S Shrivastav
Nov 23, 2011·Palliative & Supportive Care·Soenke Boettger, William Breitbart
Oct 23, 2009·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Morgane BessonJeffrey W Dalley
Aug 6, 2008·Proceedings of the National Academy of Sciences of the United States of America·W Y ChanC C Felder
Sep 9, 2006·Journal of Child and Adolescent Psychopharmacology·H K YooC Y Kim
Aug 31, 2006·Schizophrenia Bulletin·Marc De HertJoseph Peuskens
Jun 24, 2010·Journal of Clinical Psychopharmacology·Hugh MyrickRaymond F Anton
Feb 20, 2009·Pediatric Emergency Care·Samer MelhemJawaid Akhtar
Feb 13, 2007·International Clinical Psychopharmacology·Aaron P GibsonCharles Fischer
Apr 13, 2005·Perspectives in Psychiatric Care·Deborah Antai-Otong
Dec 16, 2010·Addiction Biology·Pia BäckströmPetri Hyytiä
Apr 22, 2011·Psychiatry and Clinical Neurosciences·Kazuo YamadaYoshiki Imamura
Jan 26, 2013·Annals of General Psychiatry·David M GardnerRichard Williams
Jul 29, 2009·Annals of General Psychiatry·Konstantinos N Fountoulakis, Eduard Vieta
Apr 3, 2010·Neuropsychiatric Disease and Treatment·Izchak KohenSum Lam
Feb 25, 2006·Primary Care Companion to the Journal of Clinical Psychiatry·Prasad R PadalaVishal Madaan
Jul 25, 2006·Primary Care Companion to the Journal of Clinical Psychiatry·Sriram Ramaswamy, Subhash C Bhatia
Jul 25, 2006·Primary Care Companion to the Journal of Clinical Psychiatry·Ashwin A PatkarPrakash S Masand
Jan 25, 2007·Primary Care Companion to the Journal of Clinical Psychiatry·Sandeep GroverNitin Gupta
Jan 1, 2008·Primary Care Companion to the Journal of Clinical Psychiatry·Ajay KumarSuresh Bada Math
May 30, 2013·Indian Journal of Pharmacology·Chakrakodi S ShastryBadavanahalli J Ashwathnarayana
Apr 3, 2014·Annals of General Psychiatry·Joseph PeuskensAndreas Schreiner
Apr 2, 2005·The British Journal of Psychiatry : the Journal of Mental Science·D A Cousins, A H Young
Jun 27, 2009·Neuropsychiatric Disease and Treatment·David J Muzina
Jun 10, 2011·Neuropsychiatric Disease and Treatment·Roger S McIntyreSamantha S Liauw
Jul 8, 2014·International Journal of Psychiatry in Clinical Practice·Gul EryilmazÖzgür Yorbik
Jun 9, 2005·Expert Review of Neurotherapeutics·Warren A Kinghorn, Joseph P McEvoy
Oct 22, 2011·Expert Review of Neurotherapeutics·Min-Hyeon ParkWolfgang W Fleischhacker

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Bipolar Disorder

Bipolar disorder is characterized by manic and/or depressive episodes and associated with uncommon shifts in mood, activity levels, and energy. Discover the latest research this illness here.